Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Total Current Liabilities
All obligations due within one year.
Oncolytics Biotech Inc.NASDAQ: ONCY
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 6.0% from a year ago
Total current liabilities stood at CA$5.42M at the end of Q1 FY2026, down 6.0% from a year earlier and down 11.1% from the prior quarter. Over 3 fiscal years it compounded at +28.5% a year.
Context
- Total current liabilities amounted to 66.5% of total assets at the end of Q1 FY2026, up 37.2 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
CAD · from the balance sheet
- Latest · FY2025
- 8.37M CAD
- Year-over-year change
- +25.2%
- 4-year CAGR
- +32.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.37M | +25.2% |
| FY2024 | 2024-12-31 | 6.69M | +57.8% |
| FY2023 | 2023-12-31 | 4.24M | +7.4% |
| FY2022 | 2022-12-31 | 3.95M | +46.7% |
| FY2021 | 2021-12-31 | 2.69M | — |
Total Current Liabilities vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.0% is the 3rd highest of 9, against a peer median of -14.1%.
- Total current liabilities amounts to 66.5% of total assets for ONCY, versus a peer median of 9.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $95.94M USD | +73.0% | -3.9% | 44.0% | |
| Mar 2026 | $35.24M USD | -28.7% | -13.6% | 13.9% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $11.06M USD | -9.9% | -8.3% | 8.7% |
| Mar 2026 | $10.54M USD | +13.2% | +99.5% | 11.0% | |
| Mar 2026 | $9.57M USD | -9.6% | +0.7% | 7.9% | |
| Mar 2026 | $6.73M USD | -37.5% | -8.0% | 31.1% | |
| Mar 2026 | CA$5.42M CAD | -6.0% | +28.5% | 66.5% | |
| Mar 2026 | $4.72M USD | -34.7% | -47.1% | 2.4% | |
| Mar 2026 | $3.55M USD | -18.3% | +15.4% | 6.7% | |
| Peer median (excluding ONCY) | — | -14.1% | -6.0% | 9.8% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41.26M | 11.67M | 34.91M | 15.94M | 7.14M |
| Short-term Investments | 0 | 20.47M | 0 | 0 | 0 |
| Net Receivables | 866K | 521K | 15K | 68K | 786.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 980K | 0 |
| Total Current Assets | 44.9M | 35.68M | 38.17M | 18.88M | 9.39M |
| Property, Plant & Equipment (Net) | 976K | 652K | 647K | 1.31M | 1.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 998K | 0 | 0 | 0 |
| Total Non-current Assets | 976K | 1.65M | 647K | 1.31M | 1.01M |
| Total Assets | 45.88M | 37.33M | 38.82M | 20.19M | 10.4M |
| Account Payables | 594K | 2.25M | 1.08M | 1.09M | 4.81M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 408K | 79K | 532K | 1.62M | 3.3M |
| Total Current Liabilities | 2.69M | 3.95M | 4.24M | 6.69M | 8.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 6.73M | 6.73M | 6.73M | 6.73M | 6.74M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 7.09M | 6.89M | 7.02M | 7.52M | 7.24M |
| Total Liabilities | 9.78M | 10.83M | 11.26M | 14.2M | 15.62M |
| Common Stock | 391.35M | 404.04M | 430.91M | 438.19M | 0 |
| Retained Earnings | (393.42M) | (418.25M) | (446M) | (477.71M) | (589.32M) |
| Accumulated OCI | 388K | 662K | 544K | 961K | 8.54M |
| Other Stockholders Equity | 3.62M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 36.1M | 26.5M | 27.56M | 5.98M | (5.21M) |
| Total Debt | 655K | 373K | 423K | 1.06M | 772.51K |
| Net Debt | (40.61M) | (11.29M) | (34.49M) | (14.88M) | (6.37M) |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.